07 May 2015
EMA/246014/2015
Veterinary Medicines Division

Monthly report on application procedures, guidelines and related documents for veterinary medicines

April 2015

This report, which is updated every month, provides current information related to the volume and evaluation of pre- and post-authorisation applications for medicinal products for veterinary use received by the European Medicines Agency (EMA) for the current and previous three years on:

- scientific advice requests;
- applications for initial evaluations, extensions, variations and renewals concerning marketing authorisations (MAs);
- applications for initial evaluations, extensions, modifications and extrapolations for maximum residue limits (MRLs);
- arbitration and referral procedures;
- requests for classification of products as Minor Use/Minor Species (MUMS)/limited market.

In addition, the report includes a summary table of the opinions issued by the Committee for Medicinal Products for Veterinary Use (CVMP) in the current year, as well as a list of adopted guidelines and other public guidance documents.

The purpose is only to provide ongoing factual information. Commentaries and analysis are provided in the Agency's annual reports.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Statistics on pre- and post-authorisation applications for medicinal products for veterinary use

Scientific advice requests				
	2012	2013	2014	2015
Submitted	28	40	31	**7**
Advice given	29	34	33	**6**

Scientific advice requests submitted and andvice given



Initial evaluation of marketing authorisation applications				
	2012	2013	2014	2015
Full (submitted)	12	23	11	**2**
Abridged/generics (submitted)	0	0	1	**1**
Withdrawals	1	0	3	**0**
Positive opinions	9	12	20	**2**
Negative opinions	0	0	0	**1**

Pre-authorisation: submissions of MA applications by type



Pre-authorisation: outcome of the evaluation of MA applications



Marketing authorisations				
	2012	2013	2014	2015
Granted	8	13	19	**4**
Withdrawals	3	3	1	**0**
Not renewed	0	0	0	**0**

Extensions — applications				
	2012	2013	2014	2015
Submitted	8	5	6	**1**
Withdrawals	1	0	1	**0**
Positive opinions	10	9	2	**4**
Negative opinions	0	0	0	**0**

Variations — applications submitted				
	2012	2013	2014	2015
Type-IA variations	104	175	175	**71**
Type-IB variations	96	108	118	**34**
Type-II variations	52	32	47	**16**
Transfers	2	24	1	**0**

Post-authorisation: variations and transfers submitted



Renewals — applications				
	2012	2013	2014	2015
Submitted	10	16	10	**6**
Positive opinions	10	14	15	**3**
Negative opinions	0	0	0	**0**

Establishment of MRLs for new substances[1] — applications				
	2012	2013	2014	2015
Submitted	1	6	4	**0**
Withdrawals	1	1	0	**0**
Positive opinions [2]	1	4	4	**1**
Negative opinions	0	0	0	**0**

Extensions/modifications of MRLs[3] — applications				
	2012	2013	2014	2015
Submitted	5	6	2	**1**
Withdrawals	0	0	0	**0**
Positive opinions [2,4]	8 (2)	4	8	**1**
Negative opinions	0	0	0	**0**

Review of opinions/extrapolations of MRLs[5] – requests from Commission or Member States				
	2012	2013	2014	2015
Submitted	0	1	2	**0**
Opinion [2]	0	4	2	**0**

Substances considered as not falling within the scope of Regulation (EC) No 470/2009 — requests				
	2012	2013	2014	2015
Submitted	9	16	10	**4**
Agreed	6	9	9	**6**
Not agreed	1	2	1	**0**
Scientific advice recommended	0	6	1	**1**

MRL-related submissions



[1] Establishment of MRLs for new substances under article 3 of Regulation (EC) No 470/2009.
[2] Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances previously with provisional MRLs.
[3] Extension or modification of MRLs under article 3 of Regulation (EC) No 470/2009.
[4] Re-examinations of opinions are indicated in brackets.
[5] Review of opinions under article 11 of Regulation (EC) No 470/2009 or requests under article 27 of Regulation (EC) No 470/2009.

MUMS/limited-market classification — outcome of requests				
	2012	2013	2014	2015
MUMS with financial incentives	16	10	2	**2**
MUMS without financial incentives	4	10	20	**3**
Not MUMS	1	3	7	**0**



Arbitrations and referrals				
	2012	2013	2014	2015
Arbitrations and referrals submitted	12	10	7	**0**
Opinions[6]	11 (1)	13 (3)	10 (1)	**1**

[6] Re-examination of opinions in brackets.



CVMP opinions in 2015 on medicinal products for veterinary use

Positive opinions

Product • Invented name • INN/Common name	**Marketing authorisation holder**	**Therapeutic area** • Target species • Summary of indication	**EMA/CVMP** • • Validation • • Opinion • • Active time • • Clock stop	**European Commission** • Opinion received • Transmission to EC • Decision • Notification • Official Journal
• **Coliprotec F4** • Porcine post-weaning diarrhoea vaccine (live)	• Prevtec Microbia GmbH	• Pig • Vaccine against post-weaning diarrhoea	• 12/03/2014 • 15/01/2015 • 210 • 99	• 15/01/2015 • 11/02/2015 • 16/03/2015 • 18/03/2015 • C 148 of 05/05/2015
• **Sileo** • Dexmedetomidine hydrochloride	• Orion Corporation	• Dog • Alleviation of acute anxiety and fear associated with noise in dogs.	• 16/10/2013 • 10/04/2015 • 210 • 331	• 10/04/2015

CVMP opinions in 2015 on establishment of MRLs

Positive opinions

Product • Substance	Target species	EMA/CVMP • Validation • Opinion • Active time • Clock stop	European Commission • Opinion received • Regulation • Official Journal
• Sisapronil	• Bovine, caprine	• 12/12/2013 • 15/01/2015 • 210 • 190	• 23/01/2015
• Diethylene glycol monoethyl ether	• All food producing species	• 17/09/2014 • 12/02/2015 • 148 • 0	• 16/02/2015

Arbitrations and referrals in 2015

Ongoing procedures

Type of procedure	Date • Clock start • CVMP opinion	Product • Product name • INN
• Procedure under Article 30(3) of Regulation 726/2004	• 10/01/2013 • 10/04/2015	• Not applicable • Lidocaine
• Referral under Article 35 of Directive 2001/82/EC	• 10/04/2013	• All veterinary medicinal products containing altrenogest to be administered orally to pigs and horses • Altrenogest
• Referral under Article 33(4) Directive 2001/82/EC	• 08/10/2014	• Gutal 1000 g/kg premix for medicated feeding stuff for pigs • Zinc oxide
• Procedure under Article 33(4) of Directive 2001/82/EC	• 05/11/2014	• Coglapix vakcina A.U.V. suspension for injection for pigs • *Actinobacillus pleuropneumoniae* strains serotype 1 and 2

Guidelines and working documents in 2015

CVMP quality

Reference number	Document title	Status
[Published on EMA website after adoption at CHMP]	Question and Answer document on plastic containers for eye drops.	Adopted February 2015

CVMP safety

Reference number	Document title	Status
EMA/CVMP/90250/2010	Guideline on risk characterisation and assessment of MRLs for biocides used in animal husbandry.	Adopted January 2015
EMA/CVMP/VICH/463199/2009	VICH GL48(R): Revised guideline on Studies to Evaluate the Metabolism and Residues Kinetics of Veterinary Drugs in Human Food-producing Animals: Marker Residue Depletion Studies to establish Product Withdrawal Periods.	Adopted February 2015
EMA/CVMP/VICH/463202/2009	VICH GL49(R): Revised guideline on Studies to Evaluate the Metabolism and Residues Kinetics of Veterinary Drugs in Human Food-producing Animals: Validation of Analytical Methods used in Residue Depletion Studies.	Adopted February 2015
EMA/CVMP/VICH/699251/2010	VICH GL54: Guideline on studies to evaluate the safety of residues of veterinary drugs in human food: general approach to establish an acute reference dose (ARfD), for release for public consultation in the EU at step 4 of the VICH process	Adopted March 2015

CVMP efficacy

Reference number	Document title	Status
EMEA/CVMP/EWP/005/2000-Rev.3	Revised guideline for the testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestation in dogs and	Adopted for consultation March 2015 (End of consultation, 30 September 2015)

Reference number	Document title	Status
	cats.	

CVMP pharmacovigilance

Reference number	Document title	Status
EMA/CVMP/PhVWP/390033/2014	Reflection paper on promotion of pharmacovigilance reporting.	Adopted March 2015

CVMP antimicrobials

Reference number	Document title	Status
EMA/CVMP/AWP/401740/2013	Reflection paper on the risk of antimicrobial resistance transfer from companion animals.	Adopted January 2015
EMA/CVMP/EWP/261180/2012	Revised guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances.	Adopted for consultation February 2015 (End of consultation, 31 May 2015)
EMA/CVMP/AWP/706442/2013	Draft new guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food-producing animals.	Adopted for consultation February 2015 (End of consultation, 31 August 2015)

CVMP immunologicals

Reference number	Document title	Status
EMA/CVMP/IWP/205351/2006-Rev.1	Draft revised guideline on the procedure to be followed when a batch of a vaccine finished product is suspected to be contaminated with bovine viral diarrhoea virus (BVDV).	Adopted for consultation January 2015 (End of consultation, 30 April 2015)

CVMP environmental risk assessment

Reference number	Document title	Status
EMA/CVMP/ERA/349254/2014	Draft reflection paper on poorly extractable and/or non-radiolabelled substances.	Adopted for consultation March 2015 (End of consultation, 31 August 2015)

General

Reference number	Document title	Status
EMA/CVMP/VICH/758781/2013	VICH GL53: Guideline on electronic exchange of documents: electronic file formats, for implementation.	Adopted March 2015